EASD 2019 Conference Review, reviewed by Associate Professor Neale Cohen

In this review:

DEPICT-2 shows improved glycaemic control with DAPA as an adjunct to insulin
The Open Artificial Pancreas System in T1D
CONCLUDE indicates a benefit for degludec in patients with insulin-dependent T2D
Incretin therapeutics: GLP-1 receptor agonist treatment
Glucagon in T2D
The novel glucose lowering agent imeglimin
Long-term results from COMISAIR show benefit to real time continuous glucose monitoring
Dapagliflozin improves quality of life in patients with heart failure, with or without diabetes
CREDENCE shows a role for canagliflozin in diabetic nephropathy
VERIFY shows efficacy of first line vildagliptin plus metformin combination therapy for T2D

Please login below to download this issue (PDF)